GMAB is Genmab A/S ADS — a non-dividend-paying stock. Trading at $34.22. Market cap: $21.03B.
Stock snapshot
| Price | $34.22 |
| Market cap | $21.03B |
| Sector | — |
| Exchange | XNAS |
| Pays dividend | No |
About GMAB
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Frequently asked
What is GMAB's current stock price?
GMAB (Genmab A/S ADS) is currently trading at $34.22.
Does GMAB pay a dividend?
GMAB (Genmab A/S ADS) does not currently pay a regular dividend.
Track GMAB in DiviDrip
Add GMAB to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search GMAB and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-03. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.